Pall Corp. is partnering with BioSciencesCorp, a biologics and biosimilars consulting company, to offer cost-effective manufacturing strategies and efficient upstream and downstream process equipment and facility design solutions for manufacturers.
  
The BioSciencesCorp team will leverage its industry expertise across all phases of the development process from concept to commercialization, providing service and support from the initial modeling phases through implementation. The team is also available to help with process integrity, such as quality by design, process analytic technologies, and regulatory guidance. 
 
This strategic partnership aims to provide drug manufacturers with direct access to Pall Biotech bioreactors, mixing and storage product lines, single-use downstream technologies, consumables, and inter-unit operation connections. Customers also have the option to work with Pall service teams throughout process design and development to help ensure process success.
 
“We are excited to partner with BioSciencesCorp to provide enabling technologies and services that support their customers mission-critical projects,” said Mario Philips, VP & General Manager at Pall Biotech. “Together, we can provide total solutions that today’s drug manufacturers need and make an impact where it matters most: with the patient.”
 
“Starting from feasibility phases through to transfer and training activities, BioSciencesCorp was built to offer quality guidance and support to each customer,” said Daniel Chang, executive director and founder of BioSciencesCorp. “Aligning with Pall Biotech deepens our ability to provide truly end-to-end, integrated solutions to customers from consultation through to clinical development and commercial manufacturing.”